Arthur D. Little Japan (ADL) announced policy recommendations on 20 October 2026 aimed at establishing an ecosystem to support improved patient access to regenerative medicine. It pointed to deteriorating business profitability for regenerative medicine products in Japan and said that partially reviewing the drug pricing system would be important to prevent companies from withdrawing.
Arthur D. Little Japan (ADL) announced policy recommendations on 20 October 2026 aimed at establishing an ecosystem to support improved patient access to regenerative medicine.
It said that, as business profitability for regenerative medicine products in Japan deteriorates, partially abolishing or relaxing the rules of the existing drug pricing system is important to prevent developers from withdrawing.